The Impact of Modern Retinal Imaging in AMD Detection

Age-related macular degeneration remains one of the leading causes of irreversible vision loss worldwide. 

Despite decades of research and therapeutic advances, one challenge has remained consistent: by the time AMD is clinically obvious, meaningful retinal damage has often already occurred.

February’s AMD Awareness Month provides an opportunity to reflect on how far retinal imaging has come, and how profoundly it is reshaping clinical practice. Historically, imaging largely confirmed what clinicians already suspected. 

Today, modern fundus cameras and OCT systems actively shape how AMD is detected and monitored. This shift has moved AMD care away from late confirmation and towards earlier detection, risk stratification and personalised treatment planning.

Why AMD was historically diagnosed too late

Traditional AMD diagnosis relied heavily on visible fundus changes, drusen burden and patient-reported symptoms. Colour fundus examination and photography allowed clinicians to document disease, but often only once structural changes were already well established.

Symptoms such as distortion or central vision loss typically emerge after photoreceptor or RPE compromise has progressed. As a result, opportunities for early intervention, lifestyle modification or closer monitoring were frequently missed.

Fluorescein angiography (FFA) added diagnostic value, particularly for neovascular AMD, but its invasive nature limited how often it could be used. Dye-based imaging required intravenous injection, skilled photographers and nursing support, making it resource-intensive and unsuitable for routine follow-up in many clinics. 

This model constrained capacity and reinforced a reactive approach to AMD management.

Fundus imaging and OCT have become the backbone of modern AMD diagnosis

The introduction of high-resolution OCT fundamentally changed how we view macular disease. Instead of inferring pathology from surface appearance alone, OCT provided cross-sectional insight into retinal layers, enabling earlier identification of subclinical change.

Colour fundus photography remains foundational, offering contextual information about drusen distribution, pigmentary changes and haemorrhage. When combined with OCT, it allows clinicians to correlate surface appearance with microstructural alterations beneath.

Modern fundus cameras such as iCare EIDON deliver true-colour, high-contrast images with minimal operator dependence, supporting consistent documentation across visits. For screening and follow-up environments, more automated solutions like iCare DRSplus enable efficient image capture while maintaining diagnostic confidence.

Together, fundus imaging and OCT form the backbone of contemporary AMD assessment, with each modality complementing the other.

Detecting change before vision is affected

OCT has made it possible to visualise early AMD markers that were previously invisible or ambiguous. Subtle drusen morphology, early RPE disruption, nascent outer retinal changes and subretinal hyperreflective material can now be identified long before functional vision loss occurs.

This earlier visibility means that instead of waiting for symptoms or overt progression, clinicians can identify patients who warrant closer observation, lifestyle counselling or earlier referral to medical retina services.

Early detection does not necessarily mean earlier treatment in every case, but it does allow for more informed, proactive decision making.

From observation to risk stratification

AMD management has traditionally followed a relatively uniform pathway: diagnose, observe, intervene when disease converts. Imaging has enabled a more nuanced approach.

Clinicians can now differentiate phenotypes, assess progression risk and identify eyes more likely to convert to advanced or neovascular AMD. Structural biomarkers seen on OCT, when interpreted alongside fundus findings, provide insight into disease trajectory rather than just disease presence.

This shift moves AMD care away from a simple watch-and-wait model and towards stratified monitoring strategies, often powered by AI, where follow-up intervals and imaging protocols are tailored to individual risk.

Imaging-led treatment and monitoring decisions

In neovascular AMD, OCT has become indispensable for guiding treatment initiation, monitoring response and adjusting injection intervals. Subretinal fluid, intraretinal cysts and pigment epithelial detachments can be assessed objectively, allowing clinicians to fine-tune therapy with greater precision.

The growing adoption of OCT angiography (OCTA) represents another significant step forward. OCTA allows clinicians to visualise retinal and choroidal blood flow without the need for dye injection, enabling repeated, non-invasive assessment of neovascular activity.

This is particularly valuable in follow-up clinics, where frequent imaging is required. OCTA reduces patient burden, eliminates injection-related risks and allows flow-based assessment to be integrated into routine review.

Systems such as Huvitz OCTavius support high-quality OCT and OCTA imaging, providing clinicians with detailed structural and vascular information within a streamlined workflow.

Non-invasive imaging, capacity and clinic efficiency

The move away from dye-based angiography has implications beyond patient comfort. OCTA can be performed by less experienced technicians, reducing reliance on highly specialised photographers and nursing staff.

This shift increases clinic capacity, shortens appointment times and makes advanced imaging more accessible across a wider range of clinical settings. Imaging that once required significant resources can now be integrated into standard AMD clinics with minimal disruption.

Combined or automated imaging platforms are being used in clinics to further enhance efficiency. Devices such as TowardPi BMizar and TowardPi Yalkaid support multimodal capture and automation, helping clinics manage growing AMD workloads without compromising diagnostic quality.

Personalised AMD care through advanced imaging

Higher resolution scans, wider field imaging and multimodal datasets allow clinicians to move beyond standardised pathways. AMD does not progress uniformly, and imaging now provides the tools to reflect that variability in management plans.

Patients benefit from clearer explanations, visual evidence of disease status and more tailored monitoring strategies. Clinics benefit from improved resource allocation and imaging-led confidence in the decisions they’re making. 

The future of AMD care

The future of AMD management lies in imaging that not only detects disease but predicts progression. As datasets grow and AI-supported analysis becomes more sophisticated, fundus imaging and OCT will form the foundation of preventative AMD strategies.

If you’d like to arrange a demo or you’ve got any questions about any of the retinal imaging devices mentioned above, we’d be happy to help. Get in touch by clicking the button below:

Speak to one of our experts